Latest news about Gujarat Themis Biosyn
Gujarat Themis Biosyn
401.95
-11.25(-2.72%)
Company Performance:
View Company Insights1D-2.72%
1M+5.02%
6M+6.52%
1Y+21.71%
5Y+65.10%
More news about Gujarat Themis Biosyn
20May 26
Gujarat Themis Biosyn incorporates wholly owned Japan unit
Gujarat Themis Biosyn Limited has incorporated a wholly owned subsidiary named Themis Biosyn Japan Limited on May 19, 2026, with a share capital of Ten Lakhs Yen. The subsidiary will operate in the pharmaceutical industry, and the company holds 100% of the shareholding. No specific regulatory approvals were required for the incorporation.
06May 26
Gujarat Themis Biosyn Limited Announces Postal Ballot for Special Resolutions
Gujarat Themis Biosyn Limited has announced a postal ballot via e-voting for two special resolutions regarding borrowing limits and loan provisions. The e-voting runs from 6th May to 4th June 2026, with results due by 8th June 2026.
25Apr 26
Gujarat Themis Biosyn Acquires Sanofi's Anti-TB Portfolio for €158 Million
Gujarat Themis Biosyn Limited has entered into an Asset Purchase Agreement with Sanofi to acquire 13 established branded generic products in the anti-tuberculosis and anti-infective segment for €158 million in cash. The portfolio has presence across 55+ countries in Europe, Middle East and Africa, with revenues of €66 million (FY23), €67 million (FY24), and €62 million (FY25). The asset-light transaction, which excludes manufacturing facilities and employees, is subject to antitrust and FDI approvals and is expected to close by December 2026, providing immediate access to regulated markets and enabling forward integration from intermediates to finished dosage formulations.
22Apr 26
Gujarat Themis Biosyn Shareholders Approve Director Re-appointment and Related Party Transactions via Postal Ballot
Gujarat Themis Biosyn Limited shareholders approved two key resolutions through postal ballot voting concluded on April 20, 2026. The re-appointment of Mrs. Kirandeep Madan as Non-Executive Woman Independent Director received 99.9960% approval, while material related party transactions with Themis Medicare Limited were approved with 52.5598% votes in favor. The e-voting process was conducted from March 19-April 17, 2026, through CDSL's platform with CS Ketan Ravindra Shirwadkar as scrutinizer.
09Apr 26
Gujarat Themis Biosyn Limited Opens Special Window for Share Transfer and Dematerialisation Under SEBI Circular
Gujarat Themis Biosyn Limited has opened a special window from February 05, 2026 to February 04, 2027 for shareholders to re-lodge transfer requests and dematerialise physical shares under SEBI Circular No. HD/38/13/11(2)2026-MIRSDPOD/1/3750/2026. The facility is available for shareholders who sold or purchased shares before April 01, 2019 but had not lodged them for transfer or faced rejection due to document issues. Transferred shares will be credited in demat mode with a one-year lock-in period. The company published notices in Western Times on April 8, 2026, and shareholders can contact MUFG Intime India Private Limited for assistance.
08Apr 26
Gujarat Themis Biosyn Limited Submits SEBI Certificate for Q4FY26 Compliance
Gujarat Themis Biosyn Limited submitted its quarterly certificate under SEBI Regulation 74(5) for Q4FY26, confirming proper handling of dematerialisation procedures. The certificate, issued by registrar MUFG Intime India Pvt. Ltd., was filed with BSE and NSE on 8th April, 2026, demonstrating the company's adherence to regulatory compliance requirements.
19Mar 26
Gujarat Themis Biosyn Publishes Postal Ballot Notice in Compliance with SEBI Regulations
Gujarat Themis Biosyn Limited has published its postal ballot notice in Western Times newspapers on March 19, 2026, complying with SEBI Listing Regulations. The company seeks shareholder approval for re-appointing Mrs. Kirandeept Madan as Independent Director and material related party transactions worth Rs. 50 crores with Themis Medicare Limited through remote e-voting process.
05Feb 26
Gujarat Themis Biosyn Q3FY26 Results Show Strong Performance with Strategic Expansion Plans
Gujarat Themis Biosyn delivered strong Q3FY26 performance with revenue growth of 9.74% to ₹434 crores and EBITDA margin improvement to 49.13%. The company completed its new fermentation facility expansion, appointed Krupesh Patel as new CFO, and is implementing strategic initiatives including hybrid renewable power project and forward integration into API production.
14Jan 26
Gujarat Themis Biosyn: Themis Medicare pledges 3.5 lakh shares to Jio Credit Limited
Themis Medicare Limited pledged 3,50,000 equity shares of Gujarat Themis Biosyn Limited to Jio Credit Limited on January 12, 2026, against a ₹10 crore borrowing facility. The pledge aims to repay high-interest loans and reduce finance costs. Post-transaction, Themis Medicare's total encumbered shareholding increased to 12,70,000 shares (1.38% of total capital).
07Jan 26
Gujarat Themis Biosyn Issues Postal Ballot for Director Appointment, Reports Strong Q2 Growth
Gujarat Themis Biosyn Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Mr. Rajneesh Anand as Non-Executive Non-Independent Director for a five-year term with professional fees of ₹10 lakhs per month. The company continues to demonstrate strong financial performance with Q2 net profit growing 44.44% year-on-year to ₹442.64 crores, alongside successful completion of fermentation capacity expansion that more than doubled production capabilities from 450 KL to 990 KL.
03Jan 26
Themis Medicare pledges 9.2 lakh shares of Gujarat Themis Biosyn for ₹10 crore facility
Themis Medicare Limited pledged 9,20,000 equity shares of Gujarat Themis Biosyn Limited on December 30, 2025, against a ₹10 crore facility from Jio Credit Limited. The pledge, disclosed under SEBI regulations, aims to repay high-interest loans and reduce finance costs. Post-pledge, Themis Medicare's encumbered shareholding stands at 9,20,000 shares (3.64% of pledged shares, 0.84% of total capital) while maintaining its overall 23.19% stake in Gujarat Themis Biosyn.
18Oct 25
Gujarat Themis Biosyn Doubles Fermentation Capacity with New Plant Commencement
Gujarat Themis Biosyn Limited (GTBL) has begun commercial production at its expanded Fermentation Block in Vapi, Gujarat. The new facility, operational from October 18, 2025, produces Rifamycin-S and Rifamycin-O. This expansion has increased GTBL's fermentation capacity from 450.00 KL to 990.00 KL, marking a 120% increase. The company aims to capitalize on growth opportunities in the fermentation segment with this enhanced capacity, enabling increased output and product diversification.
01Aug 25
Gujarat Themis Biosyn Reports Q1 FY2026 Results, Announces Board Changes and New API Plant
Gujarat Themis Biosyn reported Q1 FY2026 total income of ₹3,614.72 lakh and net profit of ₹926.16 lakh. The company set September 5, 2025, as the dividend record date. Board changes include appointment of Nihar Parikh as Additional Non-Executive Independent Director and cessation of Siddharth Kusumgar's term. A new API plant in Vapi, Gujarat commenced operations on May 1, 2025, aimed at strengthening the company's position in domestic and export markets.
01Aug 25
Gujarat Themis Biosyn Reports Q1 Results, Appoints New Director, and Commences API Plant Operations
Gujarat Themis Biosyn reported Q1 total income of ₹3,614.72 crore, down 8.14% YoY, with net profit after tax at ₹926.16 crore, a 30.03% decrease. The company appointed Mr. Nihar Parikh as Additional Non-Executive Independent Director and announced the start of commercial production at a new API plant in Vapi, Gujarat. September 5 set as record date for dividend eligibility.
01Aug 25
Gujarat Themis Biosyn Reports Q1 Results, Announces Board Changes and New API Plant
Gujarat Themis Biosyn Limited reported Q1 FY2025-26 results with total income of ₹3,614.72 lakhs and net profit of ₹926.16 lakhs, showing a decline from the previous year. The company set September 5 as the dividend record date. Board changes include the appointment of Mr. Nihar Parikh as an Additional Non-Executive Independent Director and the upcoming cessation of Mr. Siddharth Kusumgar's term. A new API plant in Vapi, Gujarat commenced operations on May 1, aimed at strengthening the company's position in export markets. The company has decided to focus on its core business of fermentation-based pharmaceutical intermediates and APIs, abandoning the previously planned merger with Themis Medicare Limited.
01Aug 25
Gujarat Themis Biosyn Reports Q1 Decline and Board Reshuffles
Gujarat Themis Biosyn Limited (GTBL) reported a 31.06% decrease in net profit to ₹91.00 crore and a 7.71% decline in revenue to ₹359.00 crore for Q1. The company appointed Mr. Nihar Parikh as an Additional Non-Executive Independent Director and announced the upcoming cessation of Mr. Siddharth Kusumgar's term. GTBL decided to focus on its core business of fermentation-based pharmaceutical intermediates and APIs, abandoning the proposed merger with Themis Medicare Limited. The company also began commercial production at its new API plant in Vapi, Gujarat.
20May 25
Gujarat Themis Biosyn Reports Decline in Q4 Financial Performance
Gujarat Themis Biosyn's Q4 results show a decline in key financial metrics. Revenue decreased by 10.1% to ₹377.4 crore, while net profit fell 25% to ₹120 crore compared to the previous year. EBITDA dropped 23.3% to ₹160.4 crore, with the EBITDA margin contracting to 42.5% from 49.82%. The company faces challenges across revenue, profitability, and operational efficiency.
06May 25
Gujarat Themis Biosyn Launches Commercial Production at New API Plant
Gujarat Themis Biosyn Ltd (GTBL) has commenced commercial production at its new Active Pharmaceutical Ingredient (API) plant in Gujarat. This strategic move aims to enhance the company's manufacturing capabilities and expand its market reach. The new facility is expected to strengthen GTBL's forward integration initiatives, potentially improving profit margins and supply chain control. The company is focusing on reinforcing its position in key export markets, particularly the United States and Europe. This expansion signifies GTBL's commitment to growth and innovation in the pharmaceutical sector, positioning it to meet increasing global demand for high-quality APIs.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,788.80
(+0.37%)
6,521.00
(-1.54%)
4,410.40
(-0.24%)
1,387.90
(-0.96%)
1,087.60
(-0.13%)
1,275.60
(-0.20%)
2,254.50
(-0.58%)
2,357.40
(+0.91%)
1,451.80
(-0.72%)
1,404.70
(-2.91%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
